Enovis (ENOV) Stock Price, News & Analysis

Company Overview

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients. Enovis markets products under a portfolio of healthcare brands, including DJO, Aircast, DonJoy, Chattanooga and MotionCare.

Enovis serves customers in North America, Europe and other international markets through a combination of direct sales, distributors and healthcare channels. The company was formerly known as Colfax Corporation and adopted the Enovis name in 2022 following the separation of Colfax’s fabrication technology business. Enovis is led by Chief Executive Officer Matthew Trerotola and is headquartered in Wilmington, Delaware.

Key Stats

• Today's Range: $19.83 to $22.26
• 50-Day Range: $17.44 to $26.22
• 52-Week Range: $16.70 to $32.41
• Volume: 2.52 million shs
• Average Volume: 1.34 million shs
• Market Capitalization: $1.15 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.25
• Consensus Rating: Moderate Buy

Enovis Stock Analysis - MarketRank™

Enovis scored higher than 63% of companies evaluated by MarketBeat, and ranked 359th out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Enovis has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Enovis has a consensus price target of $37.25, representing about 87.0% upside from its current price of $19.92.

Amount of Analyst Coverage

Enovis has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: -2.22%

Earnings Growth

Earnings for Enovis are expected to decrease by -2.22% in the coming year, from $3.15 to $3.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enovis is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enovis is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enovis has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.90% of the float of Enovis has been sold short.

Short Interest Ratio / Days to Cover

Enovis has a short interest ratio ("days to cover") of 8.68.

Change versus previous month

Short interest in Enovis has recently increased by 10.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enovis does not currently pay a dividend.

Dividend Growth

Enovis does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 5 news articles for Enovis this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 2 people have added Enovis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.4 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Enovis in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $449,599.00 in company stock, which represents 0.0391% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Enovis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $449,599.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.90% of the stock of Enovis is held by insiders.

Percentage Held by Institutions

98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/31/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:ENOV
• CIK: 1420800
• Web: www.enovis.com
• Phone: 302-252-9160
• Fax: 301-323-9001
• Employees: 7,802
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Enovis: $37.25
• High Price Target: $47.00
• Low Price Target: $27.00
• Potential Upside/Downside: +87.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($19.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 6.32
• P/E Growth: N/A
• Net Income: -$1.18 billion
• Net Margins: -47.96%
• Pretax Margin: -46.52%
• Return on Equity: 12.03%
• Return on Assets: 4.91%

Debt

• Debt-to-Equity Ratio: 0.84
• Current Ratio: 1.98
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $2.30 billion
• Price / Sales: 0.50
• Cash Flow: $23.44 per share
• Price / Cash Flow: 0.85
• Book Value: $26.09 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 57,669,000
• Free Float: 55,997,000
• Market Cap: $1.15 billion
• Optionable: Optionable
• Beta: 1.37